Clinical Trials on Kawasaki Syndrome

Total 34218 results

Celgene

Completed

Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q) (PASS MDS del5q)

Myelodysplastic Syndrome

Spain, United Kingdom, Denmark, Germany, France, Greece, Italy, Sweden, Belgium, United States, Luxembourg, Norway
University Hospital, Bordeaux

Active, not recruiting

Cohort Study Assessing the Treatment Strategy for High-Risk Myelodysplastic Syndromes in Patients Under 70 (COMYRE)

Myelodysplastic Syndromes

France
Gustavo Rivero
Baylor College of Medicine

Terminated

Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome (SS1)

Myelodysplastic Syndromes

United States
Assiut University

Completed

Mean Platelet Volume and Its Relation to Risk Stratification of Myelodysplastic Syndromes

Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies

Completed

Intensified Azacitidine in High Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

France
MedPacto, Inc.

Completed

Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS

Myelodysplastic Syndromes

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients

Myelodysplastic Syndrome

Italy
Genzyme, a Sanofi Company

Completed

Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States, Canada
Array Biopharma, now a wholly owned subsidiary...

Completed

A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Kura Oncology, Inc.

Terminated

Tipifarnib in Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Celgene

Completed

Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

Taiwan
University of Cincinnati
Genentech, Inc.

Withdrawn

The Role of Erlotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Istituto Clinico Humanitas

Unknown

An European Platform for Translational Research in Myelodysplastic Syndromes

Myelodysplastic Syndromes

Italy, Germany, France, Spain
Weill Medical College of Cornell University
Celgene

Terminated

Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndrome

United States
Celgene

Completed

A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care

Myelodysplastic Syndromes

United States, France, Spain, Australia, Czechia, United Kingdom, Italy, Germany, Greece, Poland, Russian Federation, Bulgaria, Sweden, Netherlands, Hungary
Eli Lilly and Company

Completed

A Study of Galunisertib in Participants With Myelodysplastic Syndromes

Myelodysplastic Syndromes

Germany, Spain, Italy
Groupe Francophone des Myelodysplasies
Merck Sharp & Dohme LLC

Terminated

Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine Failure (GFM-AZA-VOR)

Myelodysplastic Syndrome

France
St. Petersburg State Pavlov Medical University

Terminated

Nivolumab With Chemotherapy in Refractory MDS

Myelodysplastic Syndromes

Russian Federation
National Heart, Lung, and Blood Institute (NHLBI)

Completed

A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Terminated

Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
Grupo Español de Síndromes Mielodisplásicos

Completed

Spanish Registry of Erythropoietic Stimulating Agents Study (SPRESAS)

Myelodysplastic Syndrome
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS

Myelodysplastic Syndromes

Italy
Weill Medical College of Cornell University
CTI BioPharma

Completed

Study of Clinical Efficacy and Safety of Tosedostat in MDS (IST-CTI-MDS)

Myelodysplastic Syndrome

United States
Onconova Therapeutics, Inc.

Withdrawn

Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
University of Florida
Teva Pharmaceutical Industries, Ltd.

Withdrawn

A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United States
Shandong University

Unknown

Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk MDS Patients With Transfusion Dependent

Myelodysplastic Syndromes

China
Groupe Francophone des Myelodysplasies
Roche Pharma AG

Completed

Erlotinib in Higher Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

France
Apogenix GmbH

Completed

APG101 in Myelodysplastic Syndrome (APG101 in MDS)

Myelodysplastic Syndrome

Germany
The Affiliated Hospital of the Chinese Academy...
The Second Artillery General Hospital

Completed

Microtransplantation With Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic Syndromes

Myelodysplastic Syndromes

China
Ulsan University Hospital
Cooperative Study Group A for Hematology

Unknown

Lenalidomide After Failure of Hypomethylating Agents in Myelodysplastic Syndrome (VIOLET)

Myelodysplastic Syndrome

Korea, Republic of
Virginia Commonwealth University
Celgene Corporation

Completed

5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation

Completed

Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United States
University of Pittsburgh

Completed

Calcitriol and Dexamethasone in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Singapore General Hospital
Johnson & Johnson

Terminated

Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients

Myelodysplastic Syndrome

Singapore
Groupe Francophone des Myelodysplasies
Merck Sharp & Dohme LLC

Completed

Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia (GFMVOR2007)

Myelodysplastic Syndromes

France
Samsung Medical Center

Completed

Prognostic Molecular Markers in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

Korea, Republic of
Kaplan Medical Center
Weizmann Institute of Science

Unknown

The Effect of Combination Ultra Q10 and L-carnitine on the Course of Myelodysplastic Syndrome

Myelodysplastic Syndrome

Israel
The Vaccine Company

Unknown

Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
Providence Hospital

Unknown

Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
Eisai Inc.

Completed

A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndrome

United States
Johnson & Johnson Taiwan Ltd

Completed

An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

Taiwan
Janssen Korea, Ltd., Korea

Completed

A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome
Telik

Completed

Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
Janssen-Cilag Farmaceutica Ltda.
Janssen Korea, Ltd., Korea

No longer available

An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

Hong Kong, Brazil, Thailand
Texas Oncology Cancer Center
Genzyme, a Sanofi Company

Terminated

Clofarabine for Myelodysplastic Syndrome (MDS) Patients Who Failed Vidaza Treatment (tx)

Myelodysplastic Syndromes

United States
Astex Pharmaceuticals, Inc.

Completed

Decitabine Versus Supportive Care in Adults With Advanced-stage MDS

Myelodysplastic Syndrome

United States
University of Michigan Rogel Cancer Center
National Cancer Institute (NCI)

Completed

Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
European Organisation for Research and Treatment...

Completed

Infliximab in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

France, Belgium, Netherlands, Czech Republic, Italy, Germany
Fondazione Italiana Sindromi Mielodisplastiche-ETS
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Terminated

Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndromes

Myelodysplastic Syndromes

Italy
Cooperative Study Group A for Hematology

Unknown

Cyclophosphamide, Fludarabine and Antithymocyte Globulin Conditioning in Myelodysplastic Syndrome (MDS) (CyFluATG)

Myelodysplastic Syndrome

Korea, Republic of

Clinical Trials on Kawasaki Syndrome

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations